Medwave seeks buyer
This article was originally published in The Gray Sheet
Maker of non-invasive blood pressure measurement and monitoring systems is exploring "strategic alternatives," including the possible sale of the company, Medwave says April 10. The firm disclosed in its recent annual report that continued net losses and an accumulated deficit of about $34 million "raise substantial doubt about the company's ability to continue as a going concern." In January, Medwave received a delisting warning from the Nasdaq stock market when its share price traded below $1 for more than 30 days in a row...
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.